Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual combination of paxalisib and immunotherapy could advance the treatment of ...

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Aspirin has been shown to effectively reduce recurrence rates and improve disease-free survival,” said Anna Martling, MD, PhD.

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu ...

A common aromatic shrub that has served as traditional medicine for centuries could point the way toward innovative treatments for colorectal cancer ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

A randomized study has produced some hopeful news for colorectal cancer survivors with an unlikely suspect: the commonly used over-the-counter aspirin.